ASTEPRO 0.15% Rx
Generic Name and Formulations:
Azelastine HCl 0.15% (205.5mcg/spray;) aqueous nasal spray; contains benzalkonium chloride.
Indications for ASTEPRO 0.15%:
Seasonal and perennial allergic rhinitis.
Seasonal: 1 or 2 sprays in each nostril twice daily or 2 sprays in each nostril once daily. Perennial: 2 sprays in each nostril twice daily.
Avoid eyes, mouth. Pregnancy (Cat.C). Nursing mothers.
Potentiates CNS depression with alcohol, other CNS depressants. Caution with other antihistamines.
Bitter taste, nasal discomfort, epistaxis, headache, fatigue, somnolence, sneezing.
Spray—17mL (106 sprays), 30mL (200 sprays)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Improving Performance of Everyday Activities Is Critical in Schizophrenia
- Analysis Finds Lithium Maintenance Most Effective as Monotherapy in Bipolar Disorder
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Web-Based Intervention Targets Parental Behaviors That May Affect Adolescent Anxiety, Depression
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders
- Mortality Rates for Substance Use Disorders, Intentional Injuries Vary Widely By Country
- Facial Emotion Recognition Differentiates Behavioral Variant Frontotemporal Dementia From MDD
- The Challenge of Helping Uninsured Patients While Protecting Practice Finances
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed